STACKD Research is educational—not medical advice. Disclaimer
Also known as: LY3437943 · triple agonist
An investigational triple agonist (GLP-1, GIP, and glucagon receptors) studied for obesity and metabolic disease. Currently the highest-profile name in the space—widely framed as the next-generation successor to tirzepatide, with heavy search interest among fitness audiences.
Activates GLP-1, GIP, and glucagon pathways involved in appetite regulation, glucose handling, and energy expenditure. Exact contribution of each receptor in humans is still being mapped in trials.
The phase 2 obesity trial reported dose-dependent weight loss of up to 24.2% at 48 weeks versus 2.1% with placebo, and topline phase 3 results (TRIUMPH-1) reported roughly 28% average weight loss at 80 weeks—effect sizes approaching those historically associated with bariatric surgery. Results are striking but come from supervised trial settings in defined patient groups, not general fitness use.
Investigational and not broadly approved for consumer use as of last review. GI side effects are common in the class, and a dose-dependent increase in heart rate was seen in phase 2. The glucagon component raises glucose and lean-mass questions worth watching. Long-term safety and off-label athletic contexts are not well characterized. Always evaluate with a clinician using primary sources.
Start with our in-house roundups—plain-language synthesis of the research, with primary sources cited at the bottom of each.
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.
2023 · human
Dose-dependent weight loss up to 24.2% at 12 mg over 48 weeks vs 2.1% with placebo (N=338).
2023 · human
Glycemic and weight outcomes studied in type 2 diabetes populations.
Commonly discussed together
Semaglutide, tirzepatide, and retatrutide are commonly compared when people research metabolic and fat-loss peptide classes—from approved GLP-1/GIP medicines to investigational triple agonists.
These are distinct molecules with different approval statuses and trial populations. Comparison talk is educational, not a recommendation to obtain or combine them.
Fat loss · Metabolic